Completed PHASE2 INTERVENTIONAL 2-arm NCT03856866

Hydroxychloroquine Administration for Reduction of Pexophagy (HARP)

Sponsor: The Hospital for Sick Children

Conditions Peroxisome Biogenesis Disorders Zellweger Syndrome

Interventions Hydroxychloroquine Placebo

Updated 5 times since 2019 Last updated: Dec 15, 2020 Started: Jan 11, 2019 Primary completion: May 5, 2020 Completion: May 5, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Peroxisome Biogenesis Disorders and Zellweger Syndrome and is currently completed. The Hospital for Sick Children leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Mar 2019 — Apr 2020 [monthly]

Recruiting PHASE2

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Hospital for Sick Children

Data source: The Hospital for Sick Children

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada